Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Bremer

Showing results (101-110 of 106) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 106 results.
Human Gene Therapy. Clinical Development|December 20, 2015
A GLP-Compliant Toxicology and Biodistribution Study: Systemic Delivery of an rAAV9 Vector for the Treatment of Mucopolysaccharidosis IIIBAaron S Meadows, F Jason Duncan, Marybeth Camboni, et al.
Human Gene Therapy. Clinical Development|April 12, 2014
Feasibility and safety of systemic rAAV9-hNAGLU delivery for treating mucopolysaccharidosis IIIB: toxicology, biodistribution, and immunological assessments in primatesDarren A Murrey, Bartholomew J Naughton, F Jason Duncan, et al.
Annals of Neurology|October 3, 2009
Limb-girdle muscular dystrophy type 2D gene therapy restores alpha-sarcoglycan and associated proteinsJerry R Mendell, Louise R Rodino-Klapac, Xiomara Rosales-Quintero, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 23, 2013
Vascular delivery of rAAVrh74.MCK.GALGT2 to the gastrocnemius muscle of the rhesus macaque stimulates the expression of dystrophin and laminin α2 surrogatesLouis G Chicoine, Louise R Rodino-Klapac, Guohong Shao, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|November 8, 2013
Plasmapheresis eliminates the negative impact of AAV antibodies on microdystrophin gene expression following vascular deliveryL G Chicoine, C L Montgomery, W G Bremer, et al.
Annals of Neurology|October 30, 2010
Sustained alpha-sarcoglycan gene expression after gene transfer in limb-girdle muscular dystrophy, type 2DJerry R Mendell, Louise R Rodino-Klapac, Xiomara Q Rosales, et al.
Pageof 11

Showing results (101-110 of 106) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 106 results.
Human Gene Therapy. Clinical Development|December 20, 2015
A GLP-Compliant Toxicology and Biodistribution Study: Systemic Delivery of an rAAV9 Vector for the Treatment of Mucopolysaccharidosis IIIBAaron S Meadows, F Jason Duncan, Marybeth Camboni, et al.
Human Gene Therapy. Clinical Development|April 12, 2014
Feasibility and safety of systemic rAAV9-hNAGLU delivery for treating mucopolysaccharidosis IIIB: toxicology, biodistribution, and immunological assessments in primatesDarren A Murrey, Bartholomew J Naughton, F Jason Duncan, et al.
Annals of Neurology|October 3, 2009
Limb-girdle muscular dystrophy type 2D gene therapy restores alpha-sarcoglycan and associated proteinsJerry R Mendell, Louise R Rodino-Klapac, Xiomara Rosales-Quintero, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 23, 2013
Vascular delivery of rAAVrh74.MCK.GALGT2 to the gastrocnemius muscle of the rhesus macaque stimulates the expression of dystrophin and laminin α2 surrogatesLouis G Chicoine, Louise R Rodino-Klapac, Guohong Shao, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|November 8, 2013
Plasmapheresis eliminates the negative impact of AAV antibodies on microdystrophin gene expression following vascular deliveryL G Chicoine, C L Montgomery, W G Bremer, et al.
Annals of Neurology|October 30, 2010
Sustained alpha-sarcoglycan gene expression after gene transfer in limb-girdle muscular dystrophy, type 2DJerry R Mendell, Louise R Rodino-Klapac, Xiomara Q Rosales, et al.
Pageof 11